Migraine Market Forecast

Migraine Market Forecast published by Datamonitor in July, 2010. This report price starts from US $ 15200.

Introduction

Introduction

After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.

Reasons to Purchase

• Quantify the current and future size of the migraine market.
• Understand the country-specific impact of key events in the migraine market during the forecast period 2010 to 2019.
• Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2010 to 2019.

OVERVIEW

• This product contains forecasts for anti-migraine drugs across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format..
  • The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  • Introduction
  • Scope of this research
  • Research and analysis highlights
  • Key reasons to read this report
• Forecasting Methodology
  • The forecasting model:
  • General event information:
  • Event selection and quantification:
  • Event parameters:
• Disclaimer

Related Reports